Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

PVL after TTVR linked to much lower survival rate, fewer clinical benefits
TTVR has made a major impact on heart patients all over the world. Just like aortic and mitral valve replacement, however, paravalvular leak is a serious complication that can lead to much worse outcomes.
SVS quality initiative gathers data to improve vascular care
More than 7,000 physicians from a wide variety of healthcare specialties are already participating in the project.
Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban
When it came to all-cause mortality and ischemic stroke, however, the two popular DOACs were associated with comparable outcomes.
Medline recalls millions of devices due to safety risk—FDA threatens ‘regulatory action’ in warning letter
Millions of angiographic syringes were recalled due to a risk of parts becoming loose or disconnected. The FDA, unhappy with Medline's response to this situation, sent the company a new warning letter.
FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system
The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.

Excessive alcohol use increases risk of amputation in CLTI patients

Identifying patients with alcohol use disorder prior to treatment may help care teams plan ahead and anticipate potential complications.

warning safety alert recall healthcare issue

FDA shares new warning about Johnson & Johnson heart pumps after 4 injuries

This represents the latest in a series of safety concerns associated with the Impella platform. The FDA said it is still reviewing the matter and will keep the public informed as new details become available.

TAVR a safe treatment option for patients who have undergone chest radiation therapy

In fact, researchers wrote, TAVR and SAVR were linked to comparable long-term outcomes for heart patients who have previously been exposed to mediastinal radiation.

Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR

Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger patients require a valve replacement.

Death after PCI seen in just 0.5% of patients—heart attack, cardiac arrest most common causes

The new analysis included data from more than 22,000 PCI patients treated at one of two high-volume U.S. facilities. Infection was the most common noncardiac cause of death.

Gore completes acquisition of medtech company behind next-gen heart device

Gore has officially acquired Conformal Medical, the company known for an investigational LAAO device that uses a proprietary foam implant. The transaction was first announced in January.

The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

Medtronic’s RDN system receives new reimbursement approval

More than 40 million adults now have improved access to Medtronic's Symplicity Spyral renal denervation technology.

After years of implanting left atrial appendage occlusion (LAAO) devices in atrial fibrillation (AFib) patients, an interventional cardiologist with the University of Chicago Medical Center (UChicago Medicine) has developed a new device that could be a more affordable alternative to Boston Scientific’s Watchman and Abbott’s Amplatzer Amulet LAA Occluder.

Cardiologist develops new heart device that uses gel to reduce stroke risk in AFib patients

After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.

Interventional Cardiology

PVL after TTVR linked to much lower survival rate, fewer clinical benefits

SVS quality initiative gathers data to improve vascular care

Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban

Medline recalls millions of devices due to safety risk—FDA threatens ‘regulatory action’ in warning letter

FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system